Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn Lilly buys AtaiBeckley·$3.8bn Otsuka buys Transcend·$1.2bn AbbVie buys Gilgamesh·$1.2bn atai buys Beckley Psytech·terms undisclosed AbbVie takes an option on Gilgamesh·$2bn

Next issueIssue 16 · Tue 29 Sep

Regulatory

EMA, national regulators, the EU Clinical Trials Regulation and guidance in development.

9 issues

2026-09-22No. 15
The CVR is an option, and Lilly holds it
2026-09-15No. 14
Five countries, one regulator.
2026-09-08No. 13
Three authorised, one counted.
2026-09-01No. 12
Lilly’s depression trial went from one approval to four in seven days.
2026-08-25No. 11
Lilly has five authorised trials in the EU system. None of them are the drugs it just bought.
2026-08-18No. 10
A clinician, not a company, runs Germany's psilocybin compassionate use programme
- ACCESS
- REGULATORY
2026-08-04No. 9
No European application on file for the world's most advanced psilocybin programme
2026-07-28No. 8
Europe already pays for clinic-administered psychiatry. Just not for psychedelics.
- ACCESS
- REGULATORY
2026-07-21No. 7
Eli Lilly buys AtaiBeckley for $3.8B, and prices Europe out of psychedelic medicine